Follow us on Twitter
This page is updated frequently with new Linker-related patents. Subscribe to the Linker RSS feed to automatically get the update: related Linker RSS feeds.
Subscribe to updates on this page: Linker RSS
|| List of recent Linker-related patents
|Apparatus and method for inhibiting melatonin synthesis in a horse|
An apparatus for inhibiting melatonin synthesis in a horse comprises a blinker having an internal surface of which at least a part is diffusing. A source of light is positioned for direction into the horse's eye by the diffusing-surface.
|Drug delivery conjugates containing unnatural amino acids and methods for using|
Described herein are drug delivery conjugates for targeted therapy. In particular, described herein are drug delivery conjugates that include polyvalent linkers comprising one or more unnatural amino acids..
|Cross-linked polyphosphonate-sulfone composition for removal of metal ions from wastewater|
The cross-linked anionic polyelectrolyte polymer is made by cyclopolymerization of diallylaminomethylphosphonic acid, 1,1,4,4-tetraallylpiperazinium dichloride (a cross-linker), and sulfur dioxide in the presence of aibn (an initiator) in dmso at 65° c. To form a cross-linked polyzwitterionic acid (cpza).
|Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors|
The invention provides a compound for use as a protein kinase b inhibitor, the compound being a compound of the formula (i) or salts, solvates, tautomers or n-oxides thereof, wherein t is n or cr5; j1-j2 is n═c(r6), (r7)c═n, (r8)n—c(o), (r8)2c—c(o), n═n or (r7)c═c(r6); e is a monocyclic carbocyclic or heterocyclic group of 5 or 6 ring members, the heterocyclic group containing up to 3 heteroatoms selected from o, n and s; q1 is a bond or a saturated c1-3 hydrocarbon linker group, one of the carbon atoms in the linker group being optionally be replaced by an oxygen or nitrogen atom, or an adjacent pair of carbon atoms may be replaced by conrq or nrqco where rq is hydrogen or methyl, or rq is a c1-4 alkylene chain linked to r1 or a carbon atom of q1 to form a cyclic moiety; and wherein the carbon atoms of the linker group q1 may optionally bear one or more substituents selected from fluorine and hydroxy; q2 is a bond or a saturated hydrocarbon linker group containing from 1 to 3 carbon atoms, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group may optionally bear one or more substituents selected from fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the g group; and provided that when e is aryl or heteroaryl, then q2 is other than a bond; g is hydrogen, nr2r3, oh or sh provided that when e is aryl or heteroaryl and q2 is a bond, then g is hydrogen; r1 is hydrogen or an aryl or heteroaryl group, with the proviso that when r1 is hydrogen and g is nr2r3, then q2 is a bond; and r2, r3, r4, r6 and r8 are as defined in the claims.. .
|Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders|
Y is selected from the group consisting of a bond, optionally substituted c1-6 alkylene, optionally substituted benzene, pyridinyl, a polyethylene glycol linker and —(ch2)1-6o(ch2)1-6—, and methods of using such compounds for the treatment of irritable bowel syndrome, chronic kidney disease and end-stage renal disease.. .
|New conjugated molecules comprising a peptide derived from the cd4 receptor coupled to a polyanionic polypeptide for the treatment of aids|
This invention relates to a conjugated molecule comprising a peptide derived from the cd4 receptor coupled to an organic molecule by means of a linker as well as a process for its preparation. Said organic molecule comprises a 5 to 21 amino acid anionic polypeptide.
|Glucagon antagonist-gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity|
Provided herein are peptide combinations comprising a gip agonist peptide and a glucagon antagonist peptide. In some embodiments, the peptide combination is provided as a composition, e.g., a pharmaceutical composition, while in other embodiments, the peptide combination is provided as a kit.
|Crosslinked swellable polymer|
The invention is directed to stable crosslinked water-soluble swellable polymers, methods for making same, and their various uses in the hygiene and medical arts, gel electrophoresis, packaging, agriculture, the cable industry, information technology, in the food industry, papermaking, use as flocculation aids, and the like. More particularly, the invention relates to a composition comprising expandable polymeric microparticles having labile crosslinkers and stable crosslinkers, said microparticle mixed with a fluid and an unreacted tertiary crosslinker that is capable of further crosslinking the microparticle on degradation of the labile crosslinker so as to form a stable gel.
|Composition and methods for site-specific drug delivery to treat malaria and other liver diseases|
A system for selectively delivering drugs to target tissues is provided. The system includes a drug-linker-saccharide-drug conjugate (d-l-a-d1).
|Bacteriorhodopsin fusion membrane protein expression system|
An expression vector is disclosed, which comprises: a) a polynucleotide sequence encoding a bacteriorhodopsin or a mutant bacteriorhodopsin; b) a multiple cloning site; c) a t7 promoter, d) a polyhistidine tag; e) a first protease cleavage site; f) optionally a second protease cleavage site; and g) optionally a linker; wherein the mutant bacteriorhodopsin comprises the residue corresponding to asn94 of seq id no: 1. Also disclosed is a fusion membrane protein expression system, which comprises: a) a polynucleotide sequence encoding a mutant haloarcula marismortui bacteriorhodopsin/d94n (hmbri/d94n) or a haloquadratum walsbyi bacteriorhodopsin (hwbr); b) a target membrane protein; and c) a t7 promoter, operably linked to the mutant hmbri/d94n or hwbr and the target membrane protein.
|Camptothecin-binding moiety conjugates|
The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates.. .
|Diketopiperazine forming dipeptidyl linker|
The invention relates to a method for homogeneous solution phase peptide synthesis (hspps) of a n-terminal peptide fragment pep-n and a c-terminal peptide fragment c-pep, with c-pep carrying a specific diketopiperazine (dkp) comprising c-terminal protecting group, which contains a handle group hg, with hg being connected to the c-terminus of the peptide fragment; thereby this specific dkp comprising c-terminal protecting group can be selectively cleaved from the peptide as a conventionally used c-terminal protecting group. By the use of this dkp and hg comprising c-terminal protecting group, certain process steps in convergent peptide synthesis based on a combination of hspps and solid phase peptide synthesis (spps) can be avoided.
|Polyurethane foam elastomers for high temperature applications|
Molded elastomeric polyurethane foams suitable for use as gasketing and sealing devices for use in hot environments are disclosed. The foams are the reaction product of an aromatic polyisocyanate with an isocyanate-reactive composition that includes one or more polyether polyols, certain diol chain extenders, and certain low equivalent weight hydroxyl-containing cross-linkers.
Amphiphilic prodrugs of general formula a-x are disclosed, wherein a is a biologically active agent or may be metabolized to a biologically active agent; and x is r, or up to three r moieties attached to a linker, y1, y2 or y3. Self-assembly of the amphiphilic prodrugs into reverse lyotropic phases, particularly hexagonal, cubic and sponge, is disclosed..
|High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain|
The invention provides novel potent inhibitors of the ternary protein complex of nnos, psd-95, and the nmda receptor and pharmaceutical compositions comprising the inhibitors for prophylaxis and/or treatment of excitotoxic-related disease and chronic pain conditions in a subject. The inhibitors are dimeric psd-95 inhibitors comprising a first peptide or peptide analogue linked to a second peptide or peptide analogue by a linker, wherein the first and the second peptide or peptide analogue comprise at least four amide-bonded residues having a sequence ytxv or ysxv, wherein a.
|Porphyrinic compounds for use in flow cytometry|
The present invention provides a method of detecting (e.g., by flow cytometry) a target compound, cell or particle, wherein the target is labelled with a detectable luminescent compound. The method comprises utilizing as the detectable luminescent compound a compound comprising a porphyrinic macrocycle such as a porphyrin, chlorin, bacteriochlorin, or isobacteriochlorin.
|Design and synthesis of cleavable fluorescent nucleotides as reversible terminators for dna sequencing by synthesis|
This invention provides novel azido linkers for deoxynucleotide analogues having a detectable marker attached thereto.. .
|Pipeline with heat-storing properties|
The present invention relates to a process for producing pipelines with heat-storing properties, in which a) organic polyisocyanate is mixed with b) at least one polymeric compound having at least two isocyanate-reactive hydrogen atoms, c) optionally chain extender and/or crosslinker, d) catalyst, e) wax and f) optionally other assistants and/or additives, to give a first reaction mixture, and the first reaction mixture is applied to a pipe and allowed to react fully to give a first polyurethane layer. The present invention further relates to a pipeline with heat-storing properties obtainable by such a process..
|Immunogenic compositions in particulate form and methods for producing the same|
The invention relates to the field of immunology and vaccine development, in particular to the development of vaccines based on native antigen oligomers. Provided is an immunogenic composition in particulate form, comprising oligomers of a surface exposed polypeptide of pathogenic origin or tumour origin, or antigenic part thereof, said oligomers being bound non-covalently to a particulate carrier, and a pharmaceutically acceptable diluent or excipient.
|Saddle-ride vehicle blinker device|
A saddle-ride vehicle blinker device includes an elastic support member elastically supports the blinker main body at a blinker support part provided on a vehicle body. An electric wire outlet port is disposed at or in a vicinity of the elastic support member.
|Solar cell sealing film and solar cell using the sealing film|
The present invention is to provide a solar cell sealing film which has improved insulation properties and durability of adhesive properties under high-temperature environments, and solar cell using the sealing film. A solar cell sealing film consisting of a composition comprising ethylene-polar monomer copolymer and a cross-linker, wherein the composition further contains silane-coupling agent a and silane-coupling agent b, the silane-coupling a having three alkoxysilyl groups in its molecule, and the silane-coupling agent b having one alkoxysilyl group in its molecule; and a solar cell obtained by sealing photovoltaic elements in the solar cell sealing film(s)..
|Plant hormone biosensors|
The invention provides fusion proteins comprising at least two fluorescent proteins, with the fluorescent proteins emitting different wavelengths of light from one another, at least one plant hormone binding domain that changes three-dimensional conformation upon specifically binding to a plant hormone, and two linker peptides, with the first linker linking the first fluorescent protein to the n-terminus of the plant hormone binding domain and the second linker linking the second fluorescent protein to the c-terminus of the plant hormone binding domain. The invention also provides for methods of using the fusion proteins of the present invention and nucleic acids encoding the fusion proteins..
|Method for making specific products from polysaccharide molecule|
A method for preparing a specific product from a polysaccharide in which at least one hydroxyl of a saccharide unit is substituted with an ether or ester moiety. The ether or ester moiety is provided with ethenyl and/or epoxy functionality for preparing an activatable polysaccharide polymer and the activatable polysaccharide polymer with ethenyl and/or epoxy functionality is optionally reacted with an additional coupling reagent, having at least two coupling functionality for preparing polysaccharide polymer with additional activatable crosslinker.
|Double-acylated glp-1 derivatives|
The invention relates to a derivative of a glp-1 analogue, which analogue comprises a first k residue at a position corresponding to position 27 of glp-1(7-37) (seq id no: 1); a second k residue at a position corresponding to position t of glp-1(7-37), where t is an integer in the range of 7-37 except 18 and 27; and a maximum of ten amino acid changes as compared to glp-1(7-37); wherein the first k residue is designated k27, and the second k residue is designated kt; which derivative comprises two albumin binding moieties attached to k27 and kt, respectively, via a linker, wherein the albumin binding moiety comprises a protracting moiety selected from hooc—(ch2)x—co— and hooc—c6h4-0-(ch2)y—co—; in which x is an integer in the range of 6-16, and y is an integer in the range of 3-17; wherein the linker comprises an element of the formula —nh—(ch2)2—(o—(ch2)2)k—o—(ch2)n—co—, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel glp-1 analogues.
|Proviral plasmids and production of recombinant adeno-associated virus|
Proviral plasmids contain a modular gene expression cassette with one or a combination of (i) a wildtype 5′ aav2 itr sequence flanked by unique restriction sites that permit ready removal or replacement of said itr; (ii) a promoter flanked by unique restriction sites that permit ready removal or replacement of the entire promoter sequence; (iii) a polylinker sequence that permits insertion of a gene coding sequence without modification thereof, wherein the gene is operatively linked to, and under the regulatory control of, the aforementioned promoter; (iv) a bovine growth hormone polyadenylation sequence flanked by unique restriction sites that permit ready removal or replacement of said polya sequence; and (v) a wildtype 3′ aav2 itr sequence flanked by unique restriction sites that permit ready removal or replacement of the 3′ itr. These plasmids enable rapid manipulation of the components of the cassette, e.g., rapid mutation and/or replacement of any component, and thereby increase the efficiency of recombinant viral vector, e.g., raav, production..
|Method and device for producing cement clinker|
In a device for baking of clinker in a clinker, the heat generated in the furnace can be used in a particularly efficient and versatile manner if heat generated in the furnace is transferred, by means of a first heat exchanger, to a heat carrier fluid, the heated heat carrier fluid is transported through at least one line to at least one second heat exchanger, and the heat is then discharged to a heat sink, for example in order to heat a flow of flue gas to a temperature required for the dentitrifiaction thereof.. .
|Chemically amplified positive resist composition and pattern forming process|
In a chemically amplified positive resist composition comprising (a) a base resin, (b) a photoacid generator, (c) a thermal crosslinker, and (d) an organic solvent, the base resin is a specific polymer and the crosslinker is a siloxane compound. A coating of the composition is readily developable in aqueous alkaline solution.
|Articles comprising a weather-resistant adhesive layer in contact with a low surface-energy material|
One aspect of the invention is a laminate article including a first substrate layer comprising a fluorine-containing surface, a second substrate layer and an adhesive layer in contact with both the fluorine-containing surface of the first substrate layer and the second substrate layer. The adhesive layer includes a cross-linkable, pressure-sensitive acrylic adhesive and a cross-linker selected from the group consisting of epoxies, polyisocyanates, and melamines..
|Ghrelin mimetic polypeptide hapten immunoconjugates having improved solubility and immunogenicity and methods of use thereof|
Immunoconjugates for impeding weight gain and treating obesity in a subject are disclosed. The immunoconjugates comprise a ghrelin mimetic polypeptide hapten, a spacer moiety comprising one of more polyethylene glycol (peg) units, and a protein carrier moiety.
|Methods and compositions for heptameric targeting ligands|
The present invention provides a self assembly molecule having an affinity for one or more target molecules, for use in formation of a heptameric complex, comprising: a) a monomer comprising a multimerization domain of archaeal sm1 (af-sm1) protein or sm-like ribonucleoprotein from other organisms, able to interact with other molecules of the same monomer comprising a multimerization domain of af-sm1 protein or sm-like ribonucleoprotein to self-assemble into a heptamer; and b) a target binding domain or peptide attached directly or via a linker to the monomer of (a). Also provided are heptamers comprising these self assembly molecules and methods for their use in therapy, imaging and diagnostics..
|Oxidizing agents on pigments|
Hydrophilic self-cleaning coating compositions and methods to make and use the compositions are disclosed. The compositions include a pigment material made up of an inorganic pigment attached or linked to at least one oxidizing agent.
|Acetylene bridged linkers and metal-organic frameworks (mofs) produced thereof|
Described are acetylene bridged linkers, metal-organic frameworks produced thereof, processes for producing the linkers and the metal-organic frameworks, and the use of the metal-organic frameworks. The metal-organic frameworks possess an enhanced ability to adsorb and desorb high amounts of gases, in particular methane or hydrogen.
|Nanoparticle, liposomes, polymers, agents and proteins modified with reversible linkers|
Pharmaceutical, chemical and biological agents containing a reversible disulfide linker are described. These agents can also be covalently bound or contained in delivery vehicles for delivering the agents to desired targets or areas.
|Processes for the convergent synthesis of calicheamicin derivatives|
This invention describes processes for the convergent synthesis of calicheamicin derivatives, and similar analogs using bifunctional and trifunctional linker intermediates.. .
|Acid-cleavable linkers exhibiting altered rates of acid hydrolysis|
An acid-cleavable peptide linker comprising aspartic acid and proline residues is disclosed. The acid-cleavable peptide linker provides an altered sensitivity to acid-hydrolytic release of peptides of interest from fusion peptides of the formula pep1-l-pep2.
|Engineered transposon for facile construction of a random protein domain insertion library|
Methods for facile construction of a random domain insertion library (1) with optimal control of composition and length of inter-domain linker residues and (2) mediated by sticky-end ligation between host and guest dna fragments. To develop such a method, we engineered a mu transposon.
|Monomeric and polymeric linkers useful for conjugating biological molecules and other substances|
The present invention concerns monomeric or polymeric linker molecules useful in biological and chemical applications, their synthesis, and the synthesis and use of derivatives of the linkers conjugated to a variety of detectable labels and other substances. The linkers may be used, for example, in conjunction with fluorescent labels, nucleic acid or nucleic acid analog probes, and solid phase systems, and to enhance the solubility of the conjugated molecules..
|Extracellular targeted drug conjugates|
Antibodies targeting the dysadherin subunit of the human na,k-atpase signaling complex that are covalently linked via a stable linker to steroid drugs that bind the alpha subunit of that complex are useful in the treatment of cancer.. .
|Linker peptides and polypeptides comprising same|
The invention is based, at least in part, on the finding that linker peptides which lack the amino acid sequence gsg reduce or eliminate the addition of posttranslational modifications to the polypeptides which comprise them. More specifically, the novel linker peptides disclosed herein reduce the ability of enzymes to link carbohydrate adducts to polypeptides comprising these linker peptides, e.g., reduce the ability of xylosyltransferase to link xylose to polypeptides.
|Multifunctional cellulase and hemicellulase|
A multifunctional polypeptide capable of hydrolyzing cellulosic materials, xylan, and mannan is disclosed. The polypeptide includes the catalytic core (cc) of clostridium thermocellum cthe_0797 (cele), the cellulose-specific carbohydrate-binding module cbm3 of the cellulosome anchoring protein cohesion region (cipa) of clostridium thermocellum (cbm3a), and a linker region interposed between the catalytic core and the cellulose-specific carbohydrate binding module.
|Vehicle light device structure|
A vehicle light device structure includes a headlight, a blinker, a front cover, and a light shielding plate. The blinker includes a light source, a reflector, and a blinker lens.
|Thermally-activated, high temperature particulate suspending agents and methods relating thereto|
A particulate suspending agent may be useful for mitigating particulate settling in wellbore applications with high-temperature and/or at near-neutral and higher ph values. Methods of treating a wellbore may include providing a treatment fluid comprising an aqueous liquid, a plurality of particulates, and a particulate suspending agent, wherein the particulate suspending agent comprises a crosslinked polymer particulate formed by a reaction comprising a first monofunctional monomer and an orthoester crosslinker, the orthoester crosslinker comprising an orthoester linkage and at least two crosslinking moieties; and placing the treatment fluid in a wellbore penetrating a subterranean formation..
|Methods for plug cementing|
Compositions comprise polyacrylamide, a non-metallic crosslinker and a ph-adjustment material. Such compositions have utility in the context of remedial cementing, plug cementing in particular.
|Psma binding ligand-linker conjugates and methods for using|
Described herein are prostate specific membrane antigen (psma) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions.
|Conjugates containing hydrophilic spacer linkers|
Described herein are compositions and methods for use in targeted drug delivery using cell receptor binding drug delivery conjugates containing hydrophilic spacer linkers for use in imaging, diagnosing, and/or treating diseases and disease states caused by pathogenic cell populations.. .
|Fluid loss control composition and method of using the same|
Fluid loss materials including carboxymethylcellulose and zirconium-based crosslinkers may be employed as fluid loss materials in methods of treating subterranean formations. One method includes providing a treatment fluid including carboxymethylcellulose (cmc) and a crosslinker including zirconium, wherein the carboxymethylcellulose has a degree of substitution in a range of from about 0.5 to about 2.5, wherein the crosslinker including zirconium includes one selected from the group consisting of ammonium zirconium fluoride, zirconium 2-ethylhexanoate, zirconium acetate, zirconium neodecanoate, zirconium acetylacetonate, tetrakis(triethanolamine) zirconate, zirconium carbonate, ammonium zirconium carbonate, zirconyl ammonium carbonate, zirconium complex of hydroxyethyl glycine, zirconium malonate, zirconium propionate, zirconium lactate, zirconium acetate lactate, and zirconium tartrate, and placing the treatment fluid in a subterranean formation, wherein the treatment fluid controls fluid loss in a permeable portion of the subterranean formation penetrated by a wellbore..
|Conductive metal and diffusion barrier seed compositions, and methods of use in semiconductor and interlevel dielectric substrates|
A metal seed composition useful in seeding a metal diffusion barrier or conductive metal layer on a semiconductor or dielectric substrate, the composition comprising: a nanoscopic metal component that includes a metal useful as a metal diffusion barrier or conductive metal; an adhesive component for attaching said nanoscopic metal component on said semiconductor or dielectric substrate; and a linker component that links said nanoscopic metal component with said adhesive component. Semiconductor and dielectric substrates coated with the seed compositions, as well as methods for depositing the seed compositions, are also described..
A process for decarbonation of particles of raw meal, to be burnt in a clinkering kiln at a cement plant, the process includes: a) decarbonation of particles of raw meal, in a fluidised bed heat exchanger, the particles being suspended in a rising carrier gas including carbon dioxide, the fluidised bed heat exchanger having a solid heat carrier circulating counter-current relative to the carrier gas, to provide an effluent gas including carbon dioxide and decarbonated raw meal; b) separating the effluent gas and the decarbonated raw meal c) separating the effluent gas into a first and second part; cooling the first part of the effluent gas and recycling to provide carrier gas, d) isolating the second part of effluent gas e) recovering and re-heating the heat carrier and recirculating to step (a).. .
|Method for producing cement with separation of co2|
A plant for producing cement clinker from calcium carbonate-containing raw meal. A preheating stage preheats the raw meal, which preheating stage is heated by exhaust gases from a following sintering stage.
|Anti-fouling bio-hydrogel composition|
The invention comprises a biological hydrogel that is chemically stabilized with non-covalent or covalent cross-links. The biological hydrogel is used to coat surfaces of materials for submersion in marine water.
|Alphabody libraries and methods for producing the same|
The invention provides single-chain alphabody library comprising at least 100 different-sequence single-chain alphabody polypeptides, wherein said alphabody polypeptides differ from each other in at least one of a defined set of 5 to 20 variegated amino acid residue positions, and wherein at least 70% but not all of said variegated amino acid residue positions are located either in the loop, helix surface or linker region of the alphabody. The invention further provides methods for use of the alphabody libraries and alphabodies obtainable by the methods of the invention..
|Binding ligand linked drug delivery conjugates of tubulysins|
Described herein are compounds, pharmaceutical compositions and methods for treating pathogenic cell populations. The compounds described herein include conjugates of tubulysins and vitamin receptor binding ligands.
|Template directed split and mix synthesis of small molecule libraries|
The invention combines the advantages of split and mix synthesis with the advantages of template directed synthesis. The method comprises the steps of: a) adding a linker molecule l to one or more reaction wells; b) adding a molecule fragment to each of said reaction wells; c) adding an oligonucleotide identifier to each of said reaction wells; d) subjecting said wells to conditions sufficient to allow said molecule fragments and said oligonucleotide identifiers to become attached to said linker molecule, or conditions sufficient for said molecule fragments to bind to other molecule fragments and sufficient for said oligonucleotide identifiers to bind to other oligonucleotide identifiers; e) combining the contents of said one or more reaction wells; and f) contacting the resulting bifunctional molecule(s) of step e) with one or more (oligonucleotide) templates each capable of hybridizing to at least one of the oligonucleotide identifiers added in step c)..
|Polypeptide linker and method of analyzing target material using the same|
A polypeptide linker comprising an antibody-binding region and an enzyme cleavage region, and related compositions, kits, and methods of using same.. .
|Perfluorinated compounds for the non-viral transfer of nucleic acids|
The invention relates to a compound of general formula (i): a-b-c(f, g′)-d-e-f-g-a′ or a structure of general formula (ii): a-b-c-(f′, g′)-d-b-e-f-g-a′ (ii), wherein -a is at least one molecule selected from the group of the perfluorocarbons (pfcs), perfluorinated silicon compounds, and/or further perfluorinated compounds, -b is at least one predetermined breaking point in the form of a physically, chemically, or enzymatically severable bond, -c is absent or at least one linker molecule, -d is absent or at least one spacer molecule, -e is at least one molecule selected from the group containing nucleobases, nucleosides, nucleotides, oligonucleotides, nucleic, acids, modified nucleobases, modified nucleosides, modified nucleotides, modified oligonucleotides, modified nucleic acids, monomers of peptide nucleic acids, oligomers or peptide nucleic acids and peptide nucleic acids or other nucleic acid analogs, -f, f′ is absent or at least one ligand, -g, g′ is absent or at least one marker molecule, -a′ is absent or has the meaning of a, and wherein the compounds i), ii), iii), iv), v), vi) are excluded. The invention farther relates to the use of said compound for the non-viral transfer of molecule e into a cell, to a pharmaceutical composition containing said compound, and to the use of said pharmaceutical composition..
|Targeted contrast agents and uses thereof|
Described herein is a contrast agent for administration to a subject. The contrast agent includes a targeting portion that includes an unchelated aminocarboxylate functional group; a metal ion bound to a metal-complexable portion; and a linker joining the targeting portion and the metal-complexable portion of the contrast agent.
|99mtc imaging agents and methods of use|
Wherein r1 and r2 are independently an alkyl or cycloalkyl; r3 is and alkyl; x is co or so2; y is (ch2)n, c6h4, (och2ch2)n (nhch2ch2)n and (och2ch2ch2)n, or a combination thereof; z is linker group capable of conjugating to a vector; and n is an integer between 0 and 10.. .
|Cement clinker manufacturing plant|
A cement clinker manufacturing plant that includes a plant for producing purified syngas, obtained from solid waste, and process for transferring ash recovered from the ash pan of the gasifier to at least one inlet of the feedstock conversion device, which the plant includes, and/or of the furnace for the purpose of incorporating said ash into the feedstock; and a process for conveying the purified syngas to the main tuyere of the furnace and/or to at least one inlet of the feedstock conversion device.. .
|Metal-organic framework adsorbents for composite gas separation|
Metal-organic frameworks of the family m2 (2,5-dioxido-1,4-benzenedicarboxylate) wherein m=mg, mn, fe, co, cu, ni or zn are a group of porous crystalline materials formed of metal cations or clusters joined by multitopic organic linkers that can be used to isolate individual gases from a stream of combined gases. This group of adsorbant materials incorporates a high density of coordinatively-unsaturated mii centers lining the pore surfaces.
|Immunoconjugates with an intracellularly-cleavable linkage|
The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.. .
|Multi-drug ligand conjugates|
Described herein are compounds, pharmaceutical compositions and methods for treating pathogenic cell populations in a patient. The compounds described herein include conjugates of a plurality of cytotoxic drugs and vitamin receptor binding ligands.
|Vitamin receptor binding drug delivery conjugates|
The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (l), and a drug.
Popular terms: [SEARCH]
Linker topics: Crosslinker, Binding Agent, Monovalent, Polypeptide, Crystallin, Lead Selenide, Lead Sulfide, Lead Telluride, Quantum Dot, Transparent Electrode, Refraction, Virtual Machine, Relaxation, Tertiary Amine, Acrylamide
Follow us on Twitter
This listing is a sample listing of patents related to Linker for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Linker with additional patents listed. Browse our RSS directory or Search for other possible listings.